8-K: 2seventy bio Sells Hemophilia A Program and Gene Editing Technology to Novo Nordisk for up to $40 Million

2seventy bio has sold its Hemophilia A program and related gene editing technology to Novo Nordisk for up to $40 million, allowing the company to focus on its Abecma cancer therapy.

Summary

• 2seventy bio has entered into an asset purchase agreement with Novo Nordisk, selling its Hemophilia A program and megaTAL gene editing technology.
• The deal includes an upfront payment of $38 million in cash, with an additional $2 million held back for potential indemnification claims.
• Novo Nordisk will also assume certain liabilities related to the program and its employees.
• The total potential value of the deal is up to $40 million.
• The existing collaboration agreement between 2seventy bio and Novo Nordisk regarding the Hemophilia A program has been terminated.
• 2seventy bio will now focus on the development and commercialization of Abecma, its CAR T-cell therapy for multiple myeloma.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The sale provides needed cash and allows the company to focus on its core asset, but it also means the loss of a potential future revenue stream and reliance on a single product.

Positives

• The sale provides 2seventy bio with an immediate cash infusion of $38 million, with a potential additional $2 million.
• The divestiture allows 2seventy bio to focus its resources on the development and commercialization of Abecma.
• The deal transfers the Hemophilia A program to Novo Nordisk, a company with the resources to further develop the technology.
• The 2seventy bio team working on the Hemophilia A program will join Novo Nordisk, ensuring continuity of the project.

Negatives

• 2seventy bio is losing control of its Hemophilia A program and megaTAL gene editing technology.
• The company is foregoing potential future revenue from the Hemophilia A program.
• The company is now solely reliant on the success of Abecma.

Risks

• The commercial success of Abecma is not guaranteed.
• The strategic realignment to focus on Abecma may not be as successful as anticipated.
• The company may face challenges in managing its operating expenses and cash use.
• There is a risk that the company may not achieve the anticipated cost savings from the divestiture.

Future Outlook

2seventy bio will focus on the commercialization and continued development of Abecma, its CAR T-cell therapy for multiple myeloma. The company expects to leverage the proceeds from the asset sale to support this effort.

Management Comments

• Chip Baird, CEO of 2seventy bio, stated that the deal will provide the appropriate resources for the Hemophilia A program and its team.
• Chip Baird also mentioned that the divestiture supports 2seventy's exclusive focus on delivering Abecma to as many patients as possible.
• Karina Thorn, Corporate Vice President at Novo Nordisk, expressed excitement about expanding their genome editing technology platforms and developing therapies with a curative outlook for Hemophilia A.

Industry Context

This announcement reflects a trend in the biotech industry where companies are focusing on core assets and divesting non-core programs to streamline operations and improve financial performance. The sale of the Hemophilia A program allows 2seventy bio to concentrate on its lead product, Abecma, in the competitive CAR T-cell therapy market.

Comparison to Industry Standards

• The upfront payment of $38 million for an early-stage gene therapy program is within the typical range for such deals, but the total potential value of $40 million is relatively modest compared to some larger biotech acquisitions.
• Other companies such as bluebird bio and CRISPR Therapeutics have also been involved in similar deals, focusing on specific therapeutic areas and divesting non-core assets.
• The focus on Abecma aligns with the industry trend of concentrating on approved therapies with established markets, rather than early-stage research programs.

Stakeholder Impact

• Shareholders will likely view the sale positively due to the cash infusion and focus on Abecma.
• Employees working on the Hemophilia A program will transition to Novo Nordisk.
• Patients with multiple myeloma may benefit from 2seventy bio's increased focus on Abecma.
• Patients with Hemophilia A may benefit from Novo Nordisk's resources and expertise in developing the acquired program.

Next Steps

• 2seventy bio will focus on the commercialization and continued development of Abecma.
• Novo Nordisk will integrate the acquired Hemophilia A program and team into its operations.
• 2seventy bio intends to file the Purchase Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.

Key Dates

Keywords

2seventy bio, Novo Nordisk, Hemophilia A, megaTAL, gene editing, Abecma, asset sale, CAR T-cell therapy, multiple myeloma, divestiture